remoxipride has been researched along with Parkinson Disease, Secondary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casey, DE; Gerlach, J | 1 |
| Chouinard, G | 1 |
| Andersson, U; Häggström, JE; Nilsson, MI; Widerlöv, E | 1 |
1 trial(s) available for remoxipride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Blood Chemical Analysis; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Remoxipride | 1988 |
2 other study(ies) available for remoxipride and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Male; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D2; Remoxipride | 1990 |
Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Half-Life; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Prolactin; Psychiatric Status Rating Scales; Receptors, Dopamine; Receptors, Dopamine D2; Remoxipride; Schizophrenia | 1987 |